Device Dental

Ex-Hex Stock Abutments & Compone

Payments companies reported to CMS as associated with Ex-Hex Stock Abutments & Compone. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$8,804associated payments (2023-2025)

104clinicians with associated payments

1company reporting

By year

2023 $6,929

2024 $1,875

Payments reported as associated with Ex-Hex Stock Abutments & Compone, per program year, as reported to CMS.

Who makes it

Zimvie INC. $8,804 associated with Ex-Hex Stock Abutments & Compone (2023-2025)

Specialties most often involved

General Practice (Dentist) $4,646

Dentist $3,266

Oral and Maxillofacial Surgery $363

Oral and Maxillofacial Pathology $292

Prosthodontics $146

Periodontics $36.98

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Ex-Hex Stock Abutments & Compone

These are the largest totals companies reported as associated with Ex-Hex Stock Abutments & Compone. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Brittney Gallaher	Port St Lucie, FL	General Practice (Dentist)	$145.97
George Estrada	Loxahatchee, FL	Dentist	$145.97
Mark Civin	Palm Beach Gardens, FL	General Practice (Dentist)	$145.97
Sharon Browne	North Palm Beach, FL	Dentist	$145.97
Luis Boza	Iowa City, IA	Prosthodontics	$145.97
Adrian Acosta	North Palm Beach, FL	Dentist	$145.97
Jorge Alvarez	West Palm Beach, FL	General Practice (Dentist)	$145.97
Daniel Brennan	Palm Beach Gardens, FL	General Practice (Dentist)	$145.97
Christopher Chafin	Jupiter, FL	Oral and Maxillofacial Surgery	$145.97
Carlos Boudet	West Palm Beach, FL	General Practice (Dentist)	$145.97

Prescribed Ex-Hex Stock Abutments & Compone?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.